Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HALO

Halozyme Therapeutics Inc

Feb 06 • 04:00PM ET

81.23

+2.81 3.58 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI VB XBI VBK FBT VXF MDY IBB XMHQ

Scroll to Statements

Index	-	P/E	17.07	EPS (ttm)	4.76	Insider Own	1.13%	Shs Outstand	117.52M	Perf Week	13.28%
Market Cap	9.55B	Forward P/E	9.90	EPS next Y	8.21	Insider Trans	-20.56%	Shs Float	116.26M	Perf Month	8.15%
Enterprise Value	10.36B	PEG	0.31	EPS next Q	2.16	Inst Own	101.31%	Short Float	11.69%	Perf Quarter	18.93%
Income	595.49M	P/S	7.69	EPS this Y	51.34%	Inst Trans	4.23%	Short Ratio	6.03	Perf Half Y	30.81%
Sales	1.24B	P/B	18.94	EPS next Y	28.20%	ROA	27.45%	Short Interest	13.59M	Perf YTD	20.70%
Book/sh	4.29	P/C	13.61	EPS next 5Y	31.70%	ROE	124.50%	52W High	79.50 2.18%	Perf Year	40.95%
Cash/sh	5.97	P/FCF	15.86	EPS past 3/5Y	7.74% -	ROIC	45.67%	52W Low	47.50 71.01%	Perf 3Y	55.70%
Dividend Est.	-	EV/EBITDA	12.65	Sales past 3/5Y	31.82% 38.95%	Gross Margin	78.83%	Volatility	3.41% 3.21%	Perf 5Y	70.44%
Dividend TTM	-	EV/Sales	8.34	EPS Y/Y TTM	59.01%	Oper. Margin	59.33%	ATR (14)	2.37	Perf 10Y	823.07%
Dividend Ex-Date	-	Quick Ratio	1.37	Sales Y/Y TTM	31.19%	Profit Margin	47.91%	RSI (14)	73.72	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.59	EPS Q/Q	36.06%	SMA20	11.15%	Beta	0.95	Target Price	78.00
Payout	0.00%	Debt/Eq	3.00	Sales Q/Q	22.12%	SMA50	16.66%	Rel Volume	1.00	Prev Close	78.42
Employees	350	LT Debt/Eq	1.59	Earnings	Nov 03 AMC	SMA200	24.87%	Avg Volume	2.25M	Price	81.23
IPO	Mar 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.51% 4.19%	Trades		Volume	2,245,436	Change	3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Downgrade	Goldman	Neutral → Sell	$56
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform	$70
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-05-26 09:57AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
Feb-04-26 06:09PM	Silicon Motion Moves Higher On Rosy Outlook (Investor's Business Daily)
10:39AM	Google Stock: What The Buy Side Expects From Cloud Computing Business (Investor's Business Daily)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:21AM	Stock Market Today: Dow Rises Ahead Of Jobs Data; AMD Plunges On Earnings (Live Coverage) (Investor's Business Daily)
04:57PM	Loading…
Feb-03-26 04:57PM	Stock Market Today: Nasdaq Gets Hit Hardest As Techs Sink; Palantir Climbs After Earnings (Live Coverage) (Investor's Business Daily)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Feb-02-26 05:33PM	IBD Stock Of The Day Halozyme Eyes Two Buy Points; How It's 'Layering' Up For Future Growth (Investor's Business Daily)
12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-31-26 08:00AM	5 Stocks To Watch Trade Near Buy Points; Three Are Data Center Plays (Investor's Business Daily)
Jan-30-26 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Jan-29-26 01:25PM	H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating (Insider Monkey)
11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
Jan-28-26 01:58PM	Halozyme Therapeutics Projects Sustained Growth Well Into 2040 (Benzinga)
12:02PM	Loading…
12:02PM	Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s (MarketBeat)
06:30AM	Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance (PR Newswire)
06:20AM	Halozyme buys a biotech startup; Cytokinetics launches heart drug (BioPharma Dive)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-22-26 09:52PM	TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance (Insider Monkey)
Jan-20-26 04:05PM	Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update (PR Newswire)
02:38PM	Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade (Insider Monkey)
Jan-19-26 07:20PM	Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty (Motley Fool)
Jan-18-26 10:36PM	Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks (StockStory)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-13-26 09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Jan-12-26 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Jan-09-26 11:40AM	HALO or AXSM: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE (PR Newswire)
11:04PM	Loading…
Jan-07-26 11:04PM	Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
11:25AM	Smorgasbord Of Buy Points Kicks Off 2026. Google, Nvidia On The Menu. (Investor's Business Daily)
Jan-06-26 09:38AM	CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls (The Fly)
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Jan-01-26 03:30PM	Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 (StockStory)
Dec-31-25 11:41AM	Here's What Analysts Think About Halozyme Therapeutics (HALO) (Insider Monkey)
Dec-23-25 12:46PM	Halozyme Therapeutics Stock Sees Relative Strength Rating (Investor's Business Daily)
03:53AM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised) (Zacks)
Dec-19-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Dec-18-25 12:48PM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Zacks)
07:00AM	U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-09-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-08-25 04:05PM	Jim Lang Elected to Halozyme's Board of Directors (PR Newswire)
Dec-06-25 09:50AM	The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. (Motley Fool)
Dec-05-25 09:56AM	Toast upgraded, PayPal downgraded: Wall Streets top analyst calls (TipRanks)
Dec-04-25 02:22PM	Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case (The Wall Street Journal)
01:26PM	Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany (PR Newswire)
09:53AM	Toast upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly)
Dec-03-25 12:02PM	AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names (Investor's Business Daily)
11:30AM	Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? (Zacks)
Dec-01-25 12:00PM	What Makes Halozyme Therapeutics (HALO) a New Buy Stock (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
08:04AM	Meridian Growth Fund Trimmed Halozyme Therapeutics, Inc. (HALO) Following Appreciation (Insider Monkey)
Nov-27-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
09:07AM	This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside - Here's Why (Insider Monkey)
Nov-25-25 08:30AM	Halozyme to Participate in the 8th Annual Evercore Healthcare Conference (PR Newswire)
Nov-21-25 08:05AM	This Medical Technology Leader Sees Profit Growth Topping 44% (Investor's Business Daily)
Nov-18-25 08:50AM	Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery (PR Newswire)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
08:45AM	Why I Keep Buying These 10 Incredible Growth Stocks (Motley Fool)
07:00AM	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PR Newswire)
Nov-12-25 02:43PM	Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? (Investor's Business Daily)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-07-25 01:20PM	Halozyme Therapeutics Stock Sees Improved RS Rating (Investor's Business Daily)
08:30AM	FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma (PR Newswire)
Nov-06-25 11:37PM	Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-05-25 04:05PM	Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 (PR Newswire)
Nov-04-25 10:31AM	Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View (Zacks)
12:01AM	Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ... (GuruFocus.com)
Nov-03-25 06:30PM	Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:37PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Oct-28-25 12:24PM	H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90 (Insider Monkey)
10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 12:45PM	Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings? (Zacks)
10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-23-25 10:01AM	Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025? (Zacks)
Oct-22-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-21-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:30AM	Halozyme to Report Third Quarter 2025 Financial and Operating Results (PR Newswire)
Oct-20-25 12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-17-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Oct-16-25 01:51PM	Halozyme Rallies Almost 40% YTD: How Should You Play the Stock? (Zacks)
01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
10:49AM	Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? (Zacks)
Oct-06-25 09:40AM	Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? (Zacks)
Oct-02-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
07:25AM	Halozyme eyes microparticles in $900m Elektrofi acquisition (Pharmaceutical Technology)
01:35AM	Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target (Insider Monkey)
Oct-01-25 07:00AM	Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s (PR Newswire)
06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-29-25 03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
02:36PM	AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease (Zacks)
Sep-26-25 12:18PM	Encompass Health Opens First Connecticut Rehab Hospital in Danbury (Zacks)
Sep-25-25 09:59AM	HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal (Zacks)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Option Exercise	12.07	10,000	120,700	718,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Sale	77.24	20,000	1,544,820	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Sale	76.12	20,000	1,522,317	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Sale	78.64	10,000	786,366	708,719	Feb 05 07:38 PM
Helen Torley	President, CEO, Director	Feb 03 '26	Proposed Sale	74.45	150,000	11,167,500		Feb 03 04:17 PM
Connaughton Bernadette	Director	Jan 05 '26	Sale	70.25	2,000	140,500	40,123	Jan 06 06:55 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '26	Option Exercise	0.00	7,611	0	38,424	Jan 06 06:55 PM
BERNADETTE CONNAUGHTON	Director	Jan 05 '26	Proposed Sale	70.31	2,000	140,620		Jan 05 04:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Option Exercise	0.00	9,326	0	17,000	Dec 19 05:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Sale	65.19	4,263	277,905	12,737	Dec 19 05:39 PM
Connaughton Bernadette	Director	Dec 01 '25	Sale	71.60	829	59,356	42,123	Dec 01 07:50 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Option Exercise	8.11	16,569	134,375	725,288	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Sale	68.92	16,569	1,141,925	708,719	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Sale	70.55	20,000	1,410,990	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Sale	69.13	20,000	1,382,600	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Sale	68.72	20,000	1,374,339	733,719	Nov 12 06:54 PM
Connaughton Bernadette	Director	Nov 10 '25	Sale	68.48	2,000	136,960	42,952	Nov 12 05:58 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 01 '25	Sale	75.35	20,000	1,507,024	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 02 '25	Sale	71.20	20,000	1,424,083	733,719	Oct 03 06:00 PM
Torley Helen	PRESIDENT AND CEO	Oct 03 '25	Sale	69.03	20,000	1,380,638	733,719	Oct 03 06:00 PM
Connaughton Bernadette	Director	Oct 01 '25	Sale	75.24	2,000	150,481	44,952	Oct 01 06:29 PM
Helen Torley	President, CEO, Director	Oct 01 '25	Proposed Sale	73.34	136,569	10,015,970		Oct 01 04:26 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 22 '25	Sale	77.95	2,227	173,584	22,079	Sep 23 04:15 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Option Exercise	12.11	12,406	150,217	44,306	Sep 11 05:09 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Sale	75.71	20,000	1,514,267	24,306	Sep 11 05:09 PM
NICOLE LABROSSE	Officer	Sep 10 '25	Proposed Sale	76.07	22,227	1,690,808		Sep 10 04:37 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Sale	74.44	20,000	1,488,726	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Sale	74.04	20,000	1,480,772	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Sale	73.76	20,000	1,475,128	733,719	Sep 04 05:41 PM
Connaughton Bernadette	Director	Sep 02 '25	Sale	73.68	4,000	294,736	46,952	Sep 02 08:11 PM
BERNADETTE CONNAUGHTON	Director	Sep 02 '25	Proposed Sale	73.15	8,829	645,841		Sep 02 04:38 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Sale	64.32	20,000	1,286,351	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Sale	63.51	20,000	1,270,121	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Sale	63.05	20,000	1,260,917	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Sale	57.43	20,000	1,148,618	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Sale	56.43	20,000	1,128,655	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Sale	55.51	20,000	1,110,245	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Sale	53.73	20,000	1,074,620	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Sale	52.96	20,000	1,059,200	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Sale	52.57	20,000	1,051,460	733,719	Jun 24 05:40 PM
Helen Torley	President, CEO, Director	Jun 20 '25	Proposed Sale	53.15	240,000	12,756,000		Jun 20 04:25 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '25	Option Exercise	0.00	5,035	0	33,524	Jun 13 05:33 PM
Henderson Jeffrey William	Director	Apr 28 '25	Sale	60.37	4,497	271,467	28,611	Apr 28 06:04 PM
Henderson Jeffrey William	Director	Apr 01 '25	Sale	64.05	503	32,217	33,108	Apr 01 06:32 PM
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc

Upgrade your FINVIZ experience